Merck, 1.15 billion in additional turnover linked to Covid

In the challenge at Covid-19 “I want to thank our team for the fantastic work they have done. 2021 marked a record growth for Merck: financial, operational, strategic. The additional turnover in Life Science linked to Covid was 1.15 billion euros. “This was stated by Belén Garijo, president and CEO of Merck, in his speech at the press conference to present Merck’s 2021 financial results and key strategic developments. Business growth linked to the pandemic was driven by diagnostics which, for example, had a growth linked to the need for materials for Covid tests.

“Our contribution in the fight” to the pandemic “has been to have supported to date more than 80 vaccine developers along with numerous customers who require solutions for research tools, diagnostics and therapeutic products – he added – With the acquisition of AmpTec, a leading developer of mRna technology, we have further strengthened our ability to develop and manufacture mRna for use in vaccines, therapies and diagnostics. ”